Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2018

Open Access 01-12-2018 | Research

Evidence for a protective role for the rs805305 single nucleotide polymorphism of dimethylarginine dimethylaminohydrolase 2 (DDAH2) in septic shock through the regulation of DDAH activity

Authors: Simon Lambden, James Tomlinson, Sophie Piper, Anthony C. Gordon, James Leiper

Published in: Critical Care | Issue 1/2018

Login to get access

Abstract

Background

Dimethylarginine dimethylaminohydrolase 2 (DDAH2) regulates the synthesis of nitric oxide (NO) through the metabolism of the endogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine (ADMA). Pilot studies have associated the rs805305 SNP of DDAH2 with ADMA concentrations in sepsis. This study explored the impact of the rs805305 polymorphism on DDAH activity and outcome in septic shock.

Methods

We undertook a secondary analysis of data and samples collected during the Vasopressin versus noradrenaline as initial therapy in septic shock (VANISH) trial. Plasma and DNA samples isolated from 286 patients recruited into the VANISH trial were analysed. Concentrations of L-Arginine and the methylarginines ADMA and symmetric dimethylarginine (SDMA) were determined from plasma samples. Whole blood and buffy-coat samples were genotyped for polymorphisms of DDAH2. Clinical data collected during the study were used to explore the relationship between circulating methylarginines, genotype and outcome.

Results

Peak ADMA concentration over the study period was associated with a hazard ratio for death at 28 days of 3.3 (95% CI 2.0–5.4), p < 0.001. Reduced DDAH activity measured by an elevated ADMA:SDMA ratio was associated with a reduced risk of death in septic shock (p = 0.03). The rs805305 polymorphism of DDAH2 was associated with reduced DDAH activity (p = 0.004) and 28-day mortality (p = 0.02). Mean SOFA score and shock duration were also reduced in the less common G:G genotype compared to heterozygotes and C:C genotype patients (p = 0.04 and p = 0.02, respectively).

Conclusions

Plasma ADMA is a biomarker of outcome in septic shock, and reduced DDAH activity is associated with a protective effect. The polymorphism rs805305 SNP is associated with reduced mortality, which is potentially mediated by reduced DDAH2 activity.

Trial registration

ISRCTN Registry, ISRCTN20769191. Registered on 20 September 2012.
Appendix
Available only for authorised users
Literature
1.
Marshall JC. Sepsis: rethinking the approach to clinical research. J Leukoc Biol. 2008;83:471–82.CrossRef
2.
Shankar-Hari M, Bertolini G, Brunkhorst FM, Bellomo R, Annane D, Deutschman CS, Singer M. Judging quality of current septic shock definitions and criteria. Crit Care. 2015;19:1–5.CrossRef
3.
Vincent JL, Backer D. Circulatory shock. N Engl J Med. 2013;369:1726–34.
4.
Vincent JL, Gris P, Coffernils M, Leon M, Pinsky M, Reuse C. Myocardial depression characterizes the fatal course of septic shock. Surgery. 1992;111:660–7.PubMed
5.
Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 1999;27:1230–51.CrossRef
6.
De Backer D, Creteur J, Preiser J-C, Dubois M-J, Vincent J-L. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med. 2002;166:98–104.CrossRef
7.
Lagu T, Rothberg MB, Shieh M-S, Pekow PS, Steingrub JS, Lindenauer PK. What is the best method for estimating the burden of severe sepsis in the United States? J Crit Care. 2012;27:414.e1–9.CrossRef
8.
Fleischmann C, Scherag A, Adhikari NKJ, Hartog CS, Tsaganos T, Schlattmann P, Angus DC, Reinhart K. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2015;193:259–72.CrossRef
9.
Arnalich F, Hernanz A, Jiménez M, López J, Tato E, Vázquez JJ, Montiel C. Relationship between circulating levels of calcitonin gene-related peptide, nitric oxide metabolites and hemodynamic changes in human septic shock. Regul Pept. 1996;65:115–21.CrossRef
10.
11.
Endo S, Inada K, Nakae H, Arakawa N, Takakuwa T, Yamada Y, Shimamura T, Suzuki T, Taniguchi S, Yoshida M. Nitrite/nitrate oxide (NOx) and cytokine levels in patients with septic shock. Res Commun Mol Pathol Pharmacol. 1996;91:347–56.PubMed
12.
Lopez A, Lorente J, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32:21–30.CrossRef
13.
Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem. 1994;269:13725–8.PubMed
14.
Leone A, Moncada S, Vallance P, Calver A, Collier J. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572–5.CrossRef
15.
McBride AE, Silver PA. State of the Arg: protein methylation at arginine comes of age. Cell. 2001;106:5–8.CrossRef
16.
Meyer J, Richter N, Hecker M. High-performance liquid chromatographic determination of nitric oxide synthase-related arginine derivatives in vitro and in vivo. Anal Biochem. 1997;247:11–6.CrossRef
17.
Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Münzel T. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res. 2005;97:e53–9.CrossRef
18.
Caplin B, Nitsch D, Gill H, Hoefield R, Blackwell S, MacKenzie D, Cooper JA, Middleton RJ, Talmud PJ, Veitch P, Norman J, Wheeler DC, Leiper JM. Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms. Kidney Int. 2009;77:459–67.CrossRef
19.
O'Dwyer M, Dempsey F, Crowley V, Kelleher D, McManus R, Ryan T. Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study. Crit Care. 2006;10:R139.CrossRef
20.
Tea B. L-arginine and asymmetric dimethylarginine are early predictors for survival in septic patients with acute liver failure. Mediators Inflamm. 2012;2012:11.
21.
Davis JS, Darcy CJ, Yeo TW, Jones C, McNeil YR, Stephens DP, Celermajer DS, Anstey NM. Asymmetric dimethylarginine, endothelial nitric oxide bioavailability and mortality in sepsis. PLoS One. 2011;6:e17260.CrossRef
22.
Mortensen KM, Itenov TS, Haase N, Müller RB, Ostrowski SR, Johansson PI, Olsen NV, Perner A, Søe-Jensen P, Bestle MH. High levels of methylarginines were associated with increased mortality in patients with severe sepsis. Shock. 2016;46:365–72.CrossRef
23.
Winkler MS, Kluge S, Holzmann M, Moritz E, Robbe L, Bauer A, Zahrte C, Priefler M, Schwedhelm E, Böger RH, Goetz AE, Nierhaus A, Zoellner C. Markers of nitric oxide are associated with sepsis severity: an observational study. Crit Care. 2017;21:189.CrossRef
24.
Leiper JM. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. 1999;343:209–14.CrossRef
25.
Tran CT, Fox MF, Vallance P, Leiper JM. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics. 2000;68:101–5.CrossRef
26.
Tran CTL, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl. 2003;4:33–40.CrossRef
27.
Seoa H-A, Kima S-W, Jeona E-J, Jeonga J-Y, Moonb S-S, Leed W-K, Kima J-G, Leea c I-K, Park K-G. Association of the DDAH2 gene polymorphism with type 2 diabetes and hypertension. Diabetes Res Clin Pract. 2012;98:125–31.CrossRef
28.
Pérez-Hernández N, Vargas-Alarcón G, Arellano-Zapoteco R, Martínez-Rodríguez N, Fragoso JM, Aptilon-Duque G, Posadas-Sánchez R, Posadas-Romero C, Juárez-Cedillo T, Domínguez-López ML, Rodríguez-Pérez JM. Protective role of DDAH2 (rs805304) gene polymorphism in patients with myocardial infarction. Exp Mol Pathol. 2014;97:393–8.CrossRef
29.
Marra M, Marchegiani F, Ceriello A, Sirolla C, Boemi M, Franceschi C, Spazzafumo L, Testa I, Bonfigli AR, Cucchi M, Testa R. Chronic renal impairment and DDAH2-1151 A/C polymorphism determine ADMA levels in type 2 diabetic subjects. Nephrol Dial Transplant. 2013;28:964–71.CrossRef
30.
Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O’Hara B, Rossiter S, Anthony S, Vallance P. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med. 2007;13:198–203.CrossRef
31.
Wang Z, Lambden S, Taylor V, Sujkovic E, Nandi M, Tomlinson J, Dyson A, McDonald N, Caddick S, Singer M, Leiper J. Pharmacological inhibition of DDAH1 improves survival, hemodynamics and organ function in experimental septic shock. Bichem J. 2014;460:309–16.
32.
Lambden S, Martin D, Tomlinson J, Mythen M, Leiper J. Role of dimethylarginine dimethylaminohydrolase 2 in the regulation of nitric oxide synthesis in animal and observational human models of normobaric hypoxia. Lancet. 2016;387:S62.CrossRef
33.
Gordon AC, Mason AJ, Perkins GD, Ashby D, Brett SJ. Protocol for a randomised controlled trial of vasopressin versus noradrenaline as initial therapy in septic shock (VANISH). BMJ Open. 2014;4:e005866.CrossRef
34.
Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the vanish randomized clinical trial. JAMA. 2016;316:509–18.CrossRef
35.
Lambden S, Kelly P, Ahmetaj-Shala B, Wang Z, Lee B, Nandi M, Torondel B, Delahaye M, Dowsett L, Piper S, Tomlinson J, Caplin B, Colman L, Boruc O, Slaviero A, Zhao L, Oliver E, Khadayate S, Singer M, Arrigoni F, Leiper J. Dimethylarginine dimethylaminohydrolase 2 regulates nitric oxide synthesis and hemodynamics and determines outcome in polymicrobial sepsis. Arterioscler Thromb Vasc Biol. 2015;35:1382–92.CrossRef
36.
Tomlinson JAP, Caplin B, Boruc O, Bruce-Cobbold C, Cutillas P, Dormann D, Faull P, Grossman RC, Khadayate S, Mas VR, Nitsch DD, Wang Z, Norman JT, Wilcox CS, Wheeler DC, Leiper J. Reduced renal methylarginine metabolism protects against progressive kidney damage. JASN. 2015;26(12):3045–59.CrossRef
37.
Semagn K, Babu R, Hearne S, Olsen M. Single nucleotide polymorphism genotyping using Kompetitive Allele Specific PCR (KASP): overview of the technology and its application in crop improvement. Mol Breed. 2013;33:1–14.CrossRef
38.
Levinsson A, Olin A-C, Björck L, Rosengren A, Nyberg F. Nitric oxide synthase (NOS) single nucleotide polymorphisms are associated with coronary heart disease and hypertension in the INTERGENE study. Nitric Oxide. 2014;39:1–7.CrossRef
39.
Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res. 1999;43:542–8.CrossRef
40.
Davis JS, Anstey NM. Is plasma arginine concentration decreased in patients with sepsis? A systematic review and meta-analysis. Crit Care Med. 2011;39:380–5.CrossRef
41.
Weiss SL, Haymond S, Ranaivo HR, Wang D, De Jesus VR, Chace DH, Wainwright MS. Evaluation of asymmetric dimethylarginine, arginine, and carnitine metabolism in pediatric sepsis. Paediatr Crit Care Med. 2012;13:e210–8.CrossRef
42.
Umbrello M, Pavini FC, Bolgiaghi L, Carloni E, Rapido F, Gomarasca M, D'Angelo E, Iapichino G. Asymmetric and symmetric dimethylarginines: metabolism and role in severe sepsis. Crit Care. 2009;13:P361.CrossRef
43.
Carello KA, Whitesall SE, Lloyd MC, Billecke SS, D'Alecy LG. Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats. Am J Physiol Heart Circ Physiol. 2006;290:H209–16.CrossRef
44.
Boger R. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med. 2006;38:126–36.CrossRef
45.
Böger RH, Endres HG, Schwedhelm E, Darius H, Atzler D, Lüneburg N, von Stritzky B, Maas R, Thiem U, Benndorf RA, Diehm C. Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease. J Intern Med. 2011;269:349–61.CrossRef
46.
Willeit P, Freitag DF, Laukkanen JA, Chowdhury S, Gobin R, Mayr M, Di Angelantonio E, Chowdhury R. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc. 2015;4:e001833.CrossRef
47.
Maas R, Erdmann J, Lüneburg N, Stritzke J, Schwedhelm E, Meisinger C, Peters A, Weil J, Schunkert H, Böger RH, Lieb W. Polymorphisms in the promoter region of the dimethylarginine dimethylaminohydrolase 2 gene are associated with prevalence of hypertension. Pharmacol Res. 2009;60:488–93.CrossRef
Metadata
Title
Evidence for a protective role for the rs805305 single nucleotide polymorphism of dimethylarginine dimethylaminohydrolase 2 (DDAH2) in septic shock through the regulation of DDAH activity
Authors
Simon Lambden
James Tomlinson
Sophie Piper
Anthony C. Gordon
James Leiper
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2018
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-018-2277-5

Other articles of this Issue 1/2018

Critical Care 1/2018 Go to the issue

Research

Bright environmental light improves the sleepiness of nightshift ICU nurses

Research

Stress ulcer prophylaxis in intensive care unit patients receiving enteral nutrition: a systematic review and meta-analysis

Letter

Comparison of diagnostic accuracy among procalcitonin, C-reactive protein, and interleukin 6 for blood culture positivity in general ICU patients

Research

Effect of cytomegalovirus reactivation on the time course of systemic host response biomarkers in previously immunocompetent critically ill patients with sepsis: a matched cohort study

Research

Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients

Editorial

Doctor—your septic patients have scurvy!